Andros Business Summary

Andros Pharmaceuticals Co., Ltd. (6917.TWO) is a Taiwan-based biopharmaceutical firm specializing in the development of novel drug delivery systems (NDDS), particularly lipid-based liposome and microencapsulation platforms. The company generates revenue through a hybrid model of product sales, manufacturing, and technology licensing. Its primary business segments include a clinical pipeline of topical anesthetics, such as APC101 for post-herpetic neuralgia and APC201 for osteoarthritis, alongside a commercial portfolio of niche generic drugs like LALP cream and iMinos solution for alopecia. Additionally, Andros leverages its proprietary liposome technology to produce high-end skin care products, including DNA-repairing enzyme formulations. Within the competitive landscape, Andros competes with specialty biotechs such as Taiwan Liposome Company (TLC), PharmaEngine, and TTY Biopharm. It distinguishes itself as a niche leader in the topical drug delivery market, focusing on non-invasive pain management and dermatological applications rather than systemic oncology. Leadership is spearheaded by Founder, President, and CEO Dr. Ae-June Wang, an analytical biochemist with over 20 years of experience who previously served as CSO at Purzer Pharmaceutical and led drug delivery research at the Industrial Technology Research Institute (ITRI). The executive team includes Dr. Jiun-Wen Hu, who was promoted to Director of Research and Development in 2025 to oversee topical formulation innovation, and Dr. Ping-Chuan Chen, the Director of Operating, who brought extensive venture capital and management expertise from Amed Ventures upon joining in 2023. Administrative and financial oversight is managed by Director Shu-Min Ni, a veteran of financial accounting and public listings. The company is supported by a stable board and has successfully completed nine rounds of private and public financing as of early 2026, reinforcing its position on the Taipei Exchange since its 2023 listing.